Correction: Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
Jun 2020
Historique:
pubmed: 6 5 2020
medline: 6 5 2020
entrez: 6 5 2020
Statut: ppublish

Résumé

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiants

DOI: 10.1038/s41388-020-1310-8 PMID: 32366906
pubmed: 32366906
doi: 10.1038/s41388-020-1310-8
pii: 10.1038/s41388-020-1310-8
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

4619

Commentaires et corrections

Type : ErratumFor

Auteurs

M J Gray (MJ)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mgray@osip.com.

N A Dallas (NA)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

G Van Buren (G)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

L Xia (L)

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A D Yang (AD)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

R J Somcio (RJ)

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

P Gaur (P)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

L S Mangala (LS)

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

P E Vivas-Mejia (PE)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

F Fan (F)

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A M Sanguino (AM)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

G E Gallick (GE)

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

G Lopez-Berestein (G)

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A K Sood (AK)

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

L M Ellis (LM)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lellis@mdanderson.org.
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lellis@mdanderson.org.

Classifications MeSH